HomeCMVLF • OTCMKTS
add
Cellectis SA
Nakaraang pagsara
$1.25
Sakop ng taon
$1.25 - $1.50
Market cap
105.28M USD
Average na Volume
13.00
P/E ratio
-
Dividend yield
-
Primary exchange
EPA
Mga balita tungkol sa merkado
Mga Financial
Income Statement
Kita
Net na kita
| (USD) | Mar 2025info | Y/Y na pagbabago |
|---|---|---|
Kita | 12.03M | 85.10% |
Gastos sa pagpapatakbo | 26.21M | -4.33% |
Net na kita | -18.13M | -421.25% |
Net profit margin | -150.71 | -273.55% |
Kita sa bawat share | -0.17 | -21.43% |
EBITDA | -11.13M | 39.30% |
Aktuwal na % ng binabayarang buwis | — | — |
Balance Sheet
Kabuuang asset
Kabuuang sagutin
| (USD) | Mar 2025info | Y/Y na pagbabago |
|---|---|---|
Cash at mga panandaliang investment | 127.64M | 3.79% |
Kabuuang asset | 364.09M | 2.72% |
Kabuuang sagutin | 247.88M | -6.07% |
Kabuuang equity | 116.20M | — |
Natitirang share | 72.29M | — |
Presyo para makapag-book | 0.78 | — |
Return on assets | -9.48% | — |
Return on capital | -16.42% | — |
Cash Flow
Net change in cash
| (USD) | Mar 2025info | Y/Y na pagbabago |
|---|---|---|
Net na kita | -18.13M | -421.25% |
Cash mula sa mga operasyon | -17.16M | 26.40% |
Cash mula sa pag-invest | 4.22M | 305.90% |
Cash mula sa financing | -4.09M | -134.38% |
Net change in cash | -15.62M | -13.67% |
Malayang cash flow | -7.10M | 83.60% |
Tungkol
Cellectis is a French biopharmaceutical company. It develops genome-edited chimeric antigen receptor T-cell technologies for cancer immunotherapy. It has offices in Paris, New York City, and Raleigh, North Carolina. Wikipedia
Itinatag
1999
Website
Mga Empleyado
219
